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Sodium Phenylbutyrate, a Drug With Known Capacity to
Reduce Endoplasmic Reticulum Stress, Partially
Alleviates Lipid-Induced Insulin Resistance and b-Cell
Dysfunction in Humans
Changting Xiao, Adria Giacca, and Gary F. Lewis
OBJECTIVE—Chronically elevated free fatty acids contribute to
insulin resistance and pancreatic b-cell failure. Among numerous
potential factors, the involvement of endoplasmic reticulum (ER)
stress has been postulated to play a mechanistic role. Here we
examined the efﬁcacy of the chemical chaperone, sodium phenyl-
butyrate (PBA), a drug with known capacity to reduce ER stress
in animal models and in vitro, on lipid-induced insulin resistance
and b-cell dysfunction in humans.
RESEARCH DESIGN AND METHODS—Eight overweight or
obese nondiabetic men underwent four studies each, in random
order, 4 to 6 weeks apart. Two studies were preceded by 2 weeks
of oral PBA (7.5 g/day), followed by a 48-h i.v. infusion of
intralipid/heparin or saline, and two studies were preceded by
placebo treatment, followed by similar infusions. Insulin secretion
rates (ISRs) and sensitivity (SI) were assessed after the 48-h infu-
sions by hyperglycemic and hyperinsulinemic-euglycemic clamps,
respectively.
RESULTS—Lipid infusion reduced SI, which was signiﬁcantly
ameliorated by pretreatment with PBA. Absolute ISR was not
affected by any treatment; however, PBA partially ameliorated
the lipid-induced reduction in the disposition index (DI = ISR 3
SI), indicating that PBA prevented lipid-induced b-cell dysfunction.
CONCLUSIONS—These results suggest that PBA may provide
beneﬁts in humans by ameliorating the insulin resistance and
b-cell dysfunction induced by prolonged elevation of free fatty
acids. Diabetes 60:918–924, 2011
I
nsulin resistance and pancreatic b-cell failure are
hallmarks of type 2 diabetes (1). Many factors con-
tribute to the development of insulin resistance and
b-cell dysfunction, including chronically elevated
circulating free fatty acids (FFAs). Prolonged elevation of
FFAs has been consistently demonstrated to induce insulin
resistance in animals and humans (2). FFAs are essential
in maintaining basal insulin secretion in the fasted state
(3), and acute elevation of FFAs enhances glucose-stimu-
lated insulin secretion (GSIS) (4). Although the role of
prolonged elevation of FFAs on insulin secretion is more
controversial, mounting evidence points to detrimental
effects of prolonged elevation of FFAs on b-cell function
(5). b-Cell function in vivo cannot be inferred only by
absolute insulin secretion because b-cells compensate for
insulin resistance so that the product of insulin secretion
and sensitivity is a constant (disposition index [DI]) in
normal individuals (6,7). Because FFAs induce insulin re-
sistance, which would be expected to lead to compensa-
tory insulin hypersecretion, even an unchanged or mildly
elevated absolute GSIS that is not at the level anticipated
for that degree of insulin resistance indicates b-cell dys-
function, and it is the DI, not the absolute GSIS, that cor-
rectly evaluates b-cell function. In previous studies, we
and others have shown in humans, particularly in predis-
posed individuals, that prolonged elevation of FFAs lowers
DI, indicating impaired b-cell function (8–16).
The mechanisms whereby chronically elevated FFAs
impair insulin action and b-cell function are not fully un-
derstood. Several hypotheses have been proposed, in-
cluding tissue accumulation of lipids and intermediate
metabolites (17), protein kinase C activation (18–20), pro-
inﬂammatory nuclear factor (NF)-kB pathway activation
(20–22), and oxidative stress (15,23).
Recent studies in animals and humans suggest an im-
portant role of endoplasmic reticulum (ER) stress in the
development of insulin resistance and type 2 diabetes (24).
ER is a major site for newly synthesized proteins to un-
dergo posttranslational modiﬁcations and folding, a pro-
cess facilitated by chaperones and foldases. Accumulation
of unfolded proteins triggers several signal transduction
pathways (unfolded protein response) to maintain ER ho-
meostasis, and excessive accumulation of unfolded pro-
teins beyond the processing capacity of the ER leads to ER
stress (25).
In rodents, the development of insulin resistance is ac-
companied by increased ER stress in various tissues and
is prevented with alleviation of ER stress with chemical
chaperones or genetic manipulation of the unfolded pro-
tein response pathway (26,27). In obese, insulin-resistant
humans, ER stress markers are activated in the adipose
tissue (28,29), which is reduced with weight loss after
gastric bypass surgery (30). Prolonged in vitro exposure to
palmitate induces b-cell apoptosis and impairs GSIS, pos-
sibly through induction of ER stress (31–33). In type 2
diabetic patients, ER stress markers are activated in the
b-cells (34).
Although these studies suggest an important role of ER
stress in the development of insulin resistance and b-cell
failure, it remains unclear whether chronically elevated
FFAs exert their detrimental effects through induction of
ER stress in humans, and more importantly, whether cur-
rently available chemical chaperones with shown capa-
bility to reduce ER stress in animal models and in vitro
can alleviate such effects. The objective of this study,
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ORIGINAL ARTICLEtherefore, was to examine the potential efﬁcacy of sodium
phenylbutyrate (PBA), a drug with known ability to reduce
ER stress, in amelioration of lipid-induced insulin re-
sistance and b-cell dysfunction in humans. Overweight and
obese individuals were studied because they are more
susceptible to FFA-induced b-cell dysfunction (9). The
study was speciﬁcally designed to examine the effects of
FFAs independently of other factors inducing insulin re-
sistance and b-cell dysfunction in obesity.
RESEARCH DESIGN AND METHODS
Subjects. Eight overweight or obese nondiabetic men participated in the study
(Table 1). None of the participants was taking any medication or had any
known systemic illness. All subjects had normal oral glucose tolerance in
response to a 75-g oral glucose tolerance test and had a negative family history
of type 2 diabetes. Informed, written consent was obtained from all partic-
ipants in accordance with the guidelines of the Research Ethics Board of the
University Health Network, University of Toronto.
Experimental protocol. Each participant was studied on four occasions, in
random order, 4 to 6 weeks apart: 1) 2-week oral placebo, followed by in-
travenous infusion of normal saline for 48 h (SAL); 2) 2-week oral placebo
followed by intravenous infusion of intralipid (20%, 40 mL/h) plus heparin (250
U/h) for 48 h to raise plasma FFAs by about twofold (IH); 3) 2-week oral PBA
(7.5 g/day; 500-mg Buphenyl tablet, Ucyclyd Pharma, Scottsdale, AZ; ﬁve tab-
lets three times daily), followed by 48-h IH infusion as above (IH + PBA); and 4)
2-week oral PBA, followed by 48-h saline infusion (PBA). PBA was well tol-
erated by all subjects (no side effects were reported), and compliance (.95%)
was ascertained by pill counting. The dose was in the lower end of therapeutic
range for treatment of urea cycle disorder as speciﬁed in the drug monograph.
After 2 weeks of placebo or PBA, subjects were admitted to the Metabolic
Test Centre of the Toronto General Hospital for infusion of saline or intralipid
plus heparin and testing of b-cell function and insulin sensitivity. During the
hospital stay, participants were fed an American Heart Association phase 1
diet and refrained from exercise. On each occasion, on day 1 of the admission
to the Metabolic Test Centre, an intravenous catheter was placed in a super-
ﬁcial vein of one forearm for infusion of saline or intralipid plus heparin, and
for infusion of glucose and insulin during the glycemic clamps.
On day 3, after an overnight fast, a second intravenous catheter was placed
in the opposite forearm, which was maintained in a heating blanket (65°C) to
“arterialize” venous blood for blood sampling. At approximately 0800 h, a
30-min baseline sampling period was started, followed by a 2-h, 20-mmol/L
hyperglycemic clamp, as previously described (8). Urine glucose loss was
assumed to be equal between studies for the same individual because plasma
glucose levels were similar. At the end of the 2-h hyperglycemic clamp, the
intravenous dextrose infusion was slowly tapered while avoiding hypoglyce-
mia, allowing the blood glucose to return to basal level. Three hours after the
end of the hyperglycemic clamp, a hyperinsulinemic-euglycemic clamp was
started with a primed infusion of 40 mU $m
22$min
21 of insulin and 20%
dextrose, as previously described (35).
GSIS, insulin sensitivity, insulin clearance, and DI. Insulin secretion rate
(ISR) was derived from deconvolution of plasma C-peptide concentrations
during the last 30 min of the hyperglycemic clamp (36). The insulin sensitivity
index (SI) was derived from the last 30 min of the hyperinsulinemic-
euglycemic clamp by normalization of glucose infusion rate (Ginf) for
glucose and insulin, which takes into account the experimental variability, in
particular insulin variability, which is affected by insulin clearance. Insulin
clearance (ClI) was derived as insulin infusion rates divided by insulin con-
centrations during the last 30 min of the hyperinsulinemic-euglycemic clamp.
The DI was a product of the insulin secretion rate and insulin sensitivity (DI =
ISR 3 SI), where ISR and SI were derived from the hyperglycemic clamp and
the hyperinsulinemic-euglycemic clamp, respectively, as described.
Laboratory analysis. Plasma glucose was assayed at the bedside using
a Beckman Glucose Analyzer II (Beckman Instruments Corp., Fullerton, CA).
Plasma insulin and C-peptide were measured with radioimmunoassay kits
(Millipore, Billerica, MA). Plasma triglycerides (TG; Roche Diagnostics, Laval,
QC, Canada) and FFA (Wako Industrials, Osaka, Japan) were analyzed with
enzymatic colorimetric kits.
Statistics. Plasma glucose, insulin, C-peptide, TG, and FFAs were analyzed by
two-way ANOVA for repeated measures with the Tukey test to detect differ-
ences between treatments at each time and between times within treatment
during the 48-h infusion period and differences between treatments during the
last 30 min of the clamps. A value of P , 0.05 was considered signiﬁcant.
All statistical analyses were performed with SAS 8.0 software (SAS Institute,
Cary, NC).
RESULTS
Preclamp data. Plasma levels of TG and FFAs were
similar before infusion of either lipid or saline. After the
48-h lipid infusion, plasma TG and FFAs in both lipid in-
fusion groups (IH and IH + PBA) increased by approxi-
mately twofold compared with preinfusion levels (P ,
0.05). No signiﬁcant effects of the 2-week prior treatment
with oral PBA (7.5 g/day) on TG and FFAs were observed
when compared with placebo, with and without lipid in-
fusion. Therefore, the protocol achieved similar circulat-
ing FFA levels between SAL and PBA, and between IH and
IH + PBA, with the latter being signiﬁcantly elevated.
Plasma glucose, insulin, and C-peptide concentrations were
comparable in all treatment groups before and after lipid/
saline infusion (Table 2).
Hyperglycemic clamp. Plasma glucose concentrations
were elevated to approximately 20 mmol/L and were well
matched during the last 30 min steady state of the 2-h
hyperglycemic clamp (Fig. 1A). There was a nonsigniﬁcant
trend for insulin concentrations to be slightly higher in IH
and slightly lower in IH + PBA compared with SAL and
PBA (Fig. 1B). Plasma C-peptide concentrations were
comparable between treatments (Fig. 1C), and in accor-
dance, insulin secretion rates calculated by deconvolution
of C-peptide were not signiﬁcantly different between
treatments (SAL = 1801.3 6 658.5, IH = 1560.7 6 439.2,
IH + PBA = 1539.9 6 403.4, and PBA = 1588.9 6 409.3
pmol/min, respectively; Fig. 1D).
Hyperinsulinemic-euglycemic clamp. During the last 30
min of the hyperinsulinemic-euglycemic clamp, plasma
glucose levels were maintained at ;5.5 mmol/L and were
well matched between studies (Fig. 2A). To maintain
plasma glucose at this euglycemic level, a slightly lower,
although not statistically signiﬁcant, glucose infusion rate
was required in IH (31.6 6 3.2 mmol/kg/min) compared
with SAL (37.2 6 3.7 mmol/kg/min; Fig. 2B). Glucose in-
fusion rates in IH + PBA (33.1 6 3.1 mmol/kg/min) and
PBA (36.4 6 2.7 mmol/kg/min) were not signiﬁcantly dif-
ferent from SAL. IH was associated with a higher plasma
insulin concentration (700.1 6 44.1 pmol/L) versus SAL
(576.8 6 54.9 pmol/L, P , 0.05; Fig. 2C). Pretreatment with
PBA eliminated this effect, and PBA alone had similar in-
sulin concentrations to SAL (IH + PBA = 575.1 6 43 pmol/L
and PBA = 537.2 6 17.3 pmol/L). Insulin clearance was
decreased with lipid infusion (P , 0.05 IH vs. SAL), which
was reversed by PBA pretreatment in IH + PBA, whereas
TABLE 1
Characteristics of the subjects (N =8 )
Variable Mean 6 SE
Age, years 44.3 6 3.1
Weight, kg 93.6 6 3.3
Height, cm 176.3 6 2.1
BMI, kg/m
2 30.1 6 0.9
Fasting plasma levels
Glucose, mmol/L 5.11 6 0.11
Insulin, pmol/L 89.52 6 11.61
C-peptide, nmol/L 0.65 6 0.09
TG, mmol/L 1.34 6 0.28
FFA, mmol/L 0.52 6 0.05
All subjects are male.
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C-peptide levels during the hyperinsulinemic-euglycemic
clamps were not statistically different among treatments
(SAL = 1.36 6 0.16, IH = 1.78 6 0.11, IH + PBA = 1.67 6
0.12, and PBA = 1.66 6 0.11 nmol/L, P = NS). Insulin
clearance was also reduced by IH and restored by PBA
during the hyperglycemic clamps (SAL = 1.4 6 0.2, IH =
1.1 6 0.3, IH + PBA = 1.4 6 0.3, and PBA = 1.3 6 0.4 L/min,
P , 0.05 IH vs. others). Therefore, the higher insulin levels
in IH during the hyperinsulinemic-euglycemic clamps were
unlikely due to endogenous insulin secretion.
SI and DI. SI calculated during the last 30 min of the
hyperinsulinemic-euglycemic clamp indicated a signiﬁcant
35% reduction in IH versus SAL (P , 0.05), in accordance
with slightly lower Ginf and higher insulin (Fig. 3A). In IH +
PBA, this reduction was partially prevented (P = NS vs.
SAL and IH), whereas SI was unaffected in PBA (P = NS vs.
SAL and IH + PBA, P , 0.05 vs. IH). Because the absolute
TABLE 2
Fasting levels of plasma markers before and after 48-h infusion of saline or intralipid plus heparin*
SAL IH IH + PBA PBA
Glucose, mmol/L Preinfusion 5.23 6 0.14 5.03 6 0.14 5.09 6 0.17 5.13 6 0.15
Preclamp 5.23 6 0.15 5.43 6 0.22 5.50 6 0.34 5.29 6 0.22
Insulin, pmol/L Preinfusion 107.10 6 15.67 86.40 6 12.41 81.47 6 11.36 83.11 6 7.02
Preclamp 93.40 6 11.33 102.69 6 11.15 78.24 6 5.33 87.67 6 18.83
C-peptide, nmol/L Preinfusion 0.75 6 0.12 0.66 6 0.08 0.59 6 0.08 0.59 6 0.09
Preclamp 0.63 6 0.10 0.77 6 0.12 0.74 6 0.13 0.68 6 0.08
Triglyceride, mmol/L Preinfusion 1.60 6 0.46 1.28 6 0.19 1.47 6 0.32 1.40 6 0.36
Preclamp 1.58 6 0.24 2.63 6 0.36†‡§ 3.04 6 0.44†‡§ 1.63 6 0.26
Free fatty acid, mmol/L Preinfusion 0.42 6 0.08 0.43 6 0.06 0.48 6 0.07 0.50 6 0.05
Preclamp 0.38 6 0.05 0.74 6 0.04†‡§ 0.73 6 0.07†‡§ 0.38 6 0.05
Data are means 6 SE; N = 8. Clamps were performed on subjects in four randomized visits after a 48-h SAL infusion; a 48-h IH infusion; 2-week
oral PBA (7.5 g/day), followed by a 48-h IH infusion; or 2-week oral PBA, followed by a 48-h SAL infusion. Preinfusion, before start of SAL or
IH infusion. Preclamp, 48-h after start of SAL or IH infusion and before start of the clamp. †P, 0.05 vs. SAL; ‡P, 0.05 vs. PBA; §P, 0.05 vs.
preinfusion.
FIG. 1. Plasma concentrations of glucose (A), insulin (B), and C-peptide (C), and calculated insulin secretion rates (D) during the last 30 min of
the hyperglycemic clamp. Clamps were performed on subjects in four randomized visits after a 48-h SAL infusion; a 48-h IH infusion; 2-week oral
PBA (7.5 g/day), followed by a 48-h IH infusion; or 2-week oral PBA, followed by a 48-h SAL infusion. Data are means 6 SE.
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the various treatments (Fig. 1D), the DI followed a similar
pattern as SI, with a signiﬁcant 36% lower DI in IH (1.4 3
10
22 vs. 2.2 3 10
22 L
2/kg/min, IH vs. SAL P , 0.05) that was
partly prevented by PBA in IH + PBA (1.8 3 10
22 L
2/kg/min,
P = NS vs. SAL, IH, and PBA; Fig. 3B). PBA alone did not
affect DI (2.3 3 10
22 L
2/kg/min, P = NS vs. SAL).
DISCUSSION
The mechanism of lipid-induced insulin resistance and
pancreatic b-cell dysfunction is complex, and a number of
interacting mechanisms have been proposed. Chronically
elevated circulating FFAs in the setting of obesity-associated
insulin resistance or high-fat feeding, or by lipid infusion
experimental protocols, may lead to oxidative stress
FIG. 2. Plasma concentrations of glucose (A), glucose infusion rates (B), plasma concentrations of insulin (C), and calculated insulin clearance
(D) during the last 30 min of the hyperinsulinemic-euglycemic clamp. Clamps were performed on subjects in four randomized visits after a 48-h
SAL infusion; a 48-h IH infusion; 2-week oral PBA (7.5 g/day), followed by a 48-h IH infusion; or 2-week oral PBA, followed by a 48-h SAL infusion.
Data are means 6 SE. *P < 0.05 vs. SAL, †P < 0.05 vs. IH, ¶P < 0.01 vs. IH.
FIG. 3. Insulin sensitivity index calculated from the last 30 min of the hyperinsulinemic-euglycemic clamp (A) and disposition index (B). Clamps
were performed on subjects in four randomized visits after a 48-h SAL infusion; a 48-h IH infusion; 2-week oral PBA (7.5 g/day), followed by a 48-h
IH infusion; or 2-week oral PBA, followed by a 48-h SAL infusion. Data are means 6 SE. *P < 0.01 vs. SAL, ¶P < 0.05 vs. IH.
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have implicated ER stress as a possibly unifying mech-
anism in the development of insulin resistance and type
2 diabetes in experimental models (24,25). However, the
potential involvement of ER stress in lipid-induced in-
sulin resistance and b-cell dysfunction has not been
examined in humans. Here we demonstrate that PBA,
a drug with the capability to reduce ER stress in animal
models (27) and in vitro (32,39), partially prevents lipid-
induced impairment in insulin sensitivity and b-cell
function in humans. To our knowledge, this is the ﬁrst
study in humans to administer PBA in the prolonged
lipid infusion setting and to demonstrate protection
against lipotoxicity. We did not prove that PBA reduced
ER stress in humans and we cannot exclude that the
protective effects of PBA were unrelated to ER stress
relief. However, these studies raise the possibility that
agents known to relieve ER stress may prove useful in
the prevention and treatment of type 2 diabetes.
ER stress has been implicated in the development of
insulin resistance and b-cell dysfunction in animal and
cellular models. For instance, in mice with high-fat feeding
or on a genetic obesity background, development of in-
sulin resistance is associated with increased expression
of ER stress markers in various tissues (26,27). In obese
individuals with insulin resistance, ER stress markers are
increased in adipose tissue (28,29). Furthermore, gastric
bypass surgery in obese patients is associated with re-
duced ER stress in adipose tissues along with weight loss
and improved insulin sensitivity (30). ER stress markers
are increased in the islets of db/db mice (34). Increased
ER stress markers are also detected in islets of type 2
diabetic patients (34). Very limited information exists
regarding the potential role of ER stress in insulin se-
cretion per se. A recent study showed that Wolfram
syndrome 1 protein is present in b-cell secretory granules
and plays an important role in maintaining b-cell func-
tion (40). Palmitate has been shown to exert lipotoxic/
apoptotic effects on b-cells through the induction of
ER stress (31,34,39,41,42). In INS-1 cells and primary rat
islets, palmitate-induced inhibition of GSIS is ameliorated
by PBA (32).
Although modulating ER function via the use of several
small molecular, chemical chaperones, or genetic modiﬁ-
cation of ER chaperone proteins improved insulin sensi-
tivity or secretion in animal models and in vitro (27,32,43),
the feasibility and applications in humans has remained
unstudied until recently. Of the chemical chaperones, so-
dium phenylbutyrate or PBA stabilizes protein folding
(44,45) and is currently used clinically for the treatment of
urea-cycle disorders, thalassemia, and cystic ﬁbrosis, with
a satisfactory safety proﬁle.
The ﬁnding in the current study that PBA partially pre-
vented lipid-induced insulin resistance is in line with
studies in animal models and in vitro (27). Lipid infusion
for longer than 6 h, a protocol shown to induce hepatic
insulin resistance and impair b-cell function in rodents
(23,32,38), induced ER stress in the liver of mice (46). It is
therefore possible that the effect of PBA on insulin sensi-
tivity may be through amelioration of ER stress. Although
most studies indicate that ER stress may affect b-cell
survival, 48-h lipid infusion, as was used in the current
study, does not affect b-cell mass in rodents (47), which
have a higher b-cell turnover, unlike humans.
As previously discussed, palmitate-induced decrease in
b-cell function in vitro was prevented by PBA (32). It is
possible that the differing composition of fatty acids may
have differential effects on ER status at the b-cell level
(48). Intralipid, which was used in the present experi-
ments, consists predominantly of polyunsaturated fatty
acids. Although intralipid or PBA did not affect absolute
insulin secretion, amelioration of the lipid-induced re-
duction in the DI, which represents insulin secretion in
relation to insulin resistance, by PBA pretreatment of lipid-
infused humans, indicates beneﬁts to b-cell function.
Because the difference in SI and DI in the IH and IH +
PBA groups was not statistically signiﬁcant, PBA did not
completely reverse the deleterious effects of prolonged
FFA elevation, which may be due to the dose and dura-
tion of PBA treatment or multiple mechanisms of lipo-
toxicity. PBA alone did not improve insulin sensitivity
and b-cell function in this study. It is possible that the
effects of PBA can only be detected under exacerbated
conditions, such as prolonged lipid infusion in the current
study or increased obesity; thus, ER stress has been
reported in tissues of individuals with increased obesity
(29,30).
The current study does not allow us to exclude the
possibility that the beneﬁcial effects of PBA may be due to
an unknown action of the drug beyond its known anti-ER
stress properties. For instance, PBA has been reported to
activate peroxisome proliferator–activated receptor-g and
inhibit histone deacetylase activities (49). Currently, there
are no reliable plasma ER stress markers to assess tissue
ER status. Biopsy specimens, such as in adipose tissue,
may provide such information, but biopsy per se may
cause ER stress (50). In a recent study, tauroursodeox-
ycholic acid, another chemical chaperone with ER stress
reduction capability in animals, improved insulin sensitiv-
ity in morbidly obese subjects without detectable changes
in ER stress markers in extrahepatic tissues (51). This
suggests that in humans, reduction of ER stress may be in
tissues, such as the liver, that are not easily accessible to
biopsy.
PBA also prevented a decline in insulin clearance
caused by IH infusion in this study. Insulin clearance is
mediated by similar and partly overlapping pathways af-
fecting insulin sensitivity, including insulin receptor but
not insulin receptor substrate (52–54). It is therefore pos-
sible that PBA, through ER stress reduction or mecha-
nisms independent of ER function, may have affected
insulin clearance along these pathways. The mechanism
by which PBA prevents lipid-induced reduction in insulin
clearance warrants further study.
In conclusion, the current study demonstrates that PBA
may provide clinical beneﬁts in humans against insulin
resistance and b-cell dysfunction induced by prolonged
exposure to elevated circulating FFAs. Future studies
are needed to explore the mechanism of such effects
and to establish the long-term beneﬁt and safety of com-
pounds such as PBA in prediabetic and type 2 diabetic
individuals.
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